Floatz logo

Cyclophosphamide

Recurrent Lip and Oral Cavity Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Recurrent Lip and Oral Cavity Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Loren Mell, MD
Phase 2CCC
(18F)FPPRGD2
Sanjiv Sam Gambhir
Phase 1/2CCC
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC

View all 21 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →